Agreement to Advance Discovery Process

PREMIER Biosoft and JEOL have signed a co-marketing agreement for MALDIVision, a data analysis tool for advancing research involving marker studies, drug metabolite profiling, lipid and proteomics analysis. Under this agreement, JEOL will promote MALDIVision along with its JMS-S3000 SpiralTOF™ MS system.

According to Yoshihisa Ueda, the general manager of the Mass Spectrometry Business Unit at JEOL Ltd., the S3000 SpiralTOF™ has the highest mass resolving power compared to other MALDI-TOFMS on the market; it thus also poses a challenge in terms of the amount of data and images generated. “After rigorous evaluation, we found that MALDIVision can process such data flawlessly. We are quite excited that, by combining SpiralTOF and MALDIVision, now we can offer a powerful and unique solution for the cutting edge research in life science and material science.”

“Mass Spectrometry is a rapidly growing platform for biomarker discovery. This collaboration will provide the research community, especially in the Asia-Pacific region, with a powerful tool to support mass spectrometry-based imaging applications,” said Arun Apte, CEO at PREMIER Biosoft.